Cytel Opens Office in Geneva - Extends Global Clinical Development Expertise

Experienced Swiss-based team to support company’s fast growing global Clinical Research Services business

Cytel Opens Office in Geneva - Extends Global Clinical Development Expertise

<0> CytelMichael Weitz, +1-617-528-7132Director of Marketing </0>

Cytel Inc., the leading provider of Clinical Research Services, today announced the opening of a new office in Geneva, Switzerland to support the growing demand for clinical research and biostatistical consulting capabilities throughout Europe. This office further expands Cytel’s global presence, which includes offices in Boston, Philadelphia, Providence, Paris, Pune, and Hyderabad.

“The opening of our Geneva office builds on our established business in Europe and allows us to support locally-based clients with an experienced team of Biostatisticians and Programmers. This team, all formerly with Merck Serono, brings considerable industry experience and therapeutic knowledge to Cytel’s Clinical Research Services business,” said Irving Dark, Vice President, Clinical Research Services. Sebastien Gerin, former Merck Serono SA Director and Global Head of Statistical Programming leads the team.

Cytel is a leader in the design and implementation of adaptive trials and offers robust Clinical Research Services capabilities including Data Management, Biostatistics and Programming, Medical Writing, CDISC Migration and Submission Support Services. Our Strategic Consulting group offers cutting edge study design and simulation, drug supply optimization, data visualization, and recruitment and endpoint forecasting. Cytel’s functional outsourcing business supports several major pharmaceutical and biotechnology customers from our two India based locations.

Cytel’s , East, Compass, SiZ, StatXact, and LogXact are industry standards. East is used by the 25 largest pharmaceutical companies and by international regulatory authorities. , Cytel’s newest product, is being implemented by numerous sponsors to protect their trial integrity against bias and satisfying regulatory authorities.

Our mission at is to improve success rates in the development of drugs, biologics and medical devices. We do this by improving the design and implementation of clinical trials through innovative application of statistical science, operations research, and new computational methods.

We are leaders in designing and deploying adaptive trials. All 25 leading biopharma companies rely on our technology in their clinical studies.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.